Elevance Health (1ANTM) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1ANTM Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1ANTM Stock 12 Month Forecast

Average Price Target

€338.90

▲(24.18% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is €338.90 with a high forecast of €368.71 and a low forecast of €297.57. The average price target represents a 24.18% change from the last price of €272.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"243":"€243","282":"€282","321":"€321","360":"€360","399":"€399"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":368.708852,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€368.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":338.8998257536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€338.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":297.56973232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€297.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[243,282,321,360,399],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,275.2,282.3929886153846,289.58597723076923,296.7789658461538,303.9719544615385,311.16494307692307,318.35793169230766,325.5509203076923,332.7439089230769,339.9368975384615,347.12988615384614,354.32287476923074,361.5158633846154,{"y":368.708852,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,275.2,280.09998659643077,284.99997319286155,289.8999597892923,294.79994638572305,299.6999329821538,304.5999195785846,309.4999061750154,314.39989277144616,319.29987936787694,324.1998659643077,329.09985256073844,333.9998391571692,{"y":338.8998257536,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,275.2,276.92074864,278.64149728,280.36224592,282.08299456,283.8037432,285.52449184,287.24524048,288.96598912,290.68673776,292.40748640000004,294.12823504,295.84898368,{"y":297.56973232,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":374.981,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":382.345,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":353.607,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.957,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.155,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398.688,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":357.404,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":331.366,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":336.919,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.037,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.031,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€368.71

Average Price Target€338.90

Lowest Price Target€297.57

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ann Hynes

Mizuho Securities

€364.37→€347.02

Buy

27.16%

Upside

Reiterated

11/03/25

Elevance Health price target lowered to $400 from $420 at MizuhoElevance Health price target lowered to $400 from $420 at Mizuho

Lisa Gill

J.P. Morgan

€333.14→€341.81

Buy

25.25%

Upside

Reiterated

10/28/25

Elevance Health price target raised to $394 from $384 at JPMorganElevance Health price target raised to $394 from $384 at JPMorgan

Soren Coverra

TR | OpenAI - 4o

€327.93→€323.6

Hold

18.58%

Upside

Downgraded

10/26/25

AI Generated ArticleAI Generated Article

Ryan Langston

TD Cowen

€286.29→€329.67

Buy

20.80%

Upside

Reiterated

10/23/25

Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating

David S Macdonald

Truist Financial

€347.02

Buy

27.16%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Gets a Buy from Truist Financial

Ben Hendrix

RBC Capital

€269.81→€340.08

Buy

24.62%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Receives a Buy from RBC Capital

Andrew Mok CFA

Barclays

€342.68→€334.01

Buy

22.39%

Upside

Reiterated

10/22/25

Barclays Sticks to Their Buy Rating for Elevance Health (ELV)

Stephen Baxter

Wells Fargo

€357.43→€349.62

Buy

28.11%

Upside

Reiterated

10/22/25

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

€347.02

Buy

27.16%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Cantor Fitzgerald

Jason Cassorla

Guggenheim

€345.28

Buy

26.52%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Guggenheim

Lance Wilkes

Bernstein

€386.06→€364.37

Buy

33.52%

Upside

Reiterated

10/16/25

Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Erin Wright

Morgan Stanley

€274.15→€311.45

Hold

14.13%

Upside

Reiterated

10/14/25

Elevance Health price target raised to $359 from $316 at Morgan StanleyElevance Health price target raised to $359 from $316 at Morgan Stanley

Scott Fidel

Goldman Sachs

€297.57

Hold

9.04%

Upside

Initiated

10/14/25

Elevance Health (ELV) Receives a Hold from Goldman Sachs

Kevin Fischbeck

Bank of America Securities

€286.29→€320.99

Hold

17.62%

Upside

Reiterated

10/10/25

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Elevance Health (NYSE: ELV)

A.J. Rice

UBS

€368.71

Buy

35.11%

Upside

Reiterated

09/08/25

Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ann Hynes

Mizuho Securities

€364.37→€347.02

Buy

27.16%

Upside

Reiterated

11/03/25

Elevance Health price target lowered to $400 from $420 at MizuhoElevance Health price target lowered to $400 from $420 at Mizuho

Lisa Gill

J.P. Morgan

€333.14→€341.81

Buy

25.25%

Upside

Reiterated

10/28/25

Elevance Health price target raised to $394 from $384 at JPMorganElevance Health price target raised to $394 from $384 at JPMorgan

Soren Coverra

TR | OpenAI - 4o

€327.93→€323.6

Hold

18.58%

Upside

Downgraded

10/26/25

AI Generated ArticleAI Generated Article

Ryan Langston

TD Cowen

€286.29→€329.67

Buy

20.80%

Upside

Reiterated

10/23/25

Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating

David S Macdonald

Truist Financial

€347.02

Buy

27.16%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Gets a Buy from Truist Financial

Ben Hendrix

RBC Capital

€269.81→€340.08

Buy

24.62%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Receives a Buy from RBC Capital

Andrew Mok CFA

Barclays

€342.68→€334.01

Buy

22.39%

Upside

Reiterated

10/22/25

Barclays Sticks to Their Buy Rating for Elevance Health (ELV)

Stephen Baxter

Wells Fargo

€357.43→€349.62

Buy

28.11%

Upside

Reiterated

10/22/25

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

€347.02

Buy

27.16%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Cantor Fitzgerald

Jason Cassorla

Guggenheim

€345.28

Buy

26.52%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Guggenheim

Lance Wilkes

Bernstein

€386.06→€364.37

Buy

33.52%

Upside

Reiterated

10/16/25

Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Erin Wright

Morgan Stanley

€274.15→€311.45

Hold

14.13%

Upside

Reiterated

10/14/25

Elevance Health price target raised to $359 from $316 at Morgan StanleyElevance Health price target raised to $359 from $316 at Morgan Stanley

Scott Fidel

Goldman Sachs

€297.57

Hold

9.04%

Upside

Initiated

10/14/25

Elevance Health (ELV) Receives a Hold from Goldman Sachs

Kevin Fischbeck

Bank of America Securities

€286.29→€320.99

Hold

17.62%

Upside

Reiterated

10/10/25

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Elevance Health (NYSE: ELV)

A.J. Rice

UBS

€368.71

Buy

35.11%

Upside

Reiterated

09/08/25

Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month

xxx

Success Rate

16/27 ratings generated profit

Average Return

+1.63%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.63% per trade.

3 Months

xxx

Success Rate

17/30 ratings generated profit

Average Return

-1.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.67% of your transactions generating a profit, with an average return of -1.40% per trade.

1 Year

A.J. RiceUBS

Success Rate

21/30 ratings generated profit

Average Return

+16.34%

reiterated a buy rating 2 months ago

Copying A.J. Rice's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +16.34% per trade.

2 Years

xxx

Success Rate

26/30 ratings generated profit

Average Return

+40.07%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +40.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1ANTM Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1ANTM has received 36 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 1ANTM average Analyst price target in the past 3 months is 338.90.

Each month's total comprises the sum of three months' worth of ratings.

1ANTM Financial Forecast

1ANTM Earnings Forecast

Next quarter’s earnings estimate for 1ANTM is €2.75 with a range of €2.24 to €3.43. The previous quarter’s EPS was €5.24. 1ANTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 1ANTM has Preformed in-line its overall industry.

1ANTM Sales Forecast

Next quarter’s sales forecast for 1ANTM is €43.24B with a range of €42.05B to €45.63B. The previous quarter’s sales results were €44.06B. 1ANTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 1ANTM has Preformed in-line its overall industry.

1ANTM Stock Forecast FAQ

What is IT:1ANTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 338.90.

What is IT:1ANTM’s upside potential, based on the analysts’ average price target?

Elevance Health has 24.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Elevance Health a Buy, Sell or Hold?

Elevance Health has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is Elevance Health’s share price target?

The average share price target for Elevance Health is 338.90. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €368.71 ,and the lowest forecast is €297.57. The average share price target represents 24.18% Increase from the current price of €272.9.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Elevance Health?

To buy shares of IT:1ANTM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Elevance Health (1ANTM) Stock Forecast & Price Target

1ANTM Analyst Ratings

1ANTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

1ANTM Analyst Recommendation Trends

1ANTM Financial Forecast

1ANTM Earnings Forecast

1ANTM Sales Forecast

1ANTM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts